Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
p acnes corneal ulcer endopthalmitis kaposi esotropia intraocular uveitis optic neuritis anisocoria retinitisYour Article Summary
See Latest ArticlesEffect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography
Acta Ophthalmologica, 05/26/09
Leydolt C et al. - The 6- and 12-month follow-up of repeated intravitreal bevacizumab therapy in eyes with neovascular AMD demonstrated stabilization of vision and no safety concerns. An OCT-based retreatment strategy appears appropriate in the management of patients treated with intravitreal bevacizumab.
Related Articles
Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration
Retina, 11/11/09
Relevance Score: 68%
Statin Use and the Incidence of Advanced Age-Related Macular Degeneration in the Complications of Age-Related Macular Degeneration Prevention Trial
Ophthalmology, 10/28/09
Relevance Score: 68%
siRNA therapeutics for age-related macular degeneration: promises and pitfalls
Expert Review of Ophthalmology, 10/22/09
Relevance Score: 68%
Bevacizumab vs Ranibizumab for Age-related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial
American Journal of Ophthalmology, 10/07/09
Relevance Score: 67%
The pathogenic role of the canonical Wnt pathway in age-related macular degeneration
Investigative Ophthalmology and Visual Science, 11/18/09
Relevance Score: 66%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome
Graefe's Archive for Clinical and Experimental Ophthalmology, 03/19/10
Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years
Graefe's Archive for Clinical and Experimental Ophthalmology, 03/19/10
Applanation Tonometry Versus Dynamic Contour Tonometry in Eyes Treated With Latanoprost
Journal of Glaucoma, 03/19/10
Today in Retina...keeping you current
Receive free subspecialty "5-minute updates" via email
Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome
Graefe's Archive for Clinical and Experimental Ophthalmology, 03/19/10
Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years
Graefe's Archive for Clinical and Experimental Ophthalmology, 03/19/10
Contrast sensitivity after intravitreal antivascular endothelial growth factor therapy for myopic choroidal neovascularization
Graefe's Archive for Clinical and Experimental Ophthalmology, 03/19/10
Article Search
Sponsor